#5-05E. Predicting the Future: Risk Models for Psoriatic Arthritis in New-Onset Psoriasis (Lancet Rheumatol, 2026)

Have you ever wondered which of your newly diagnosed psoriasis patients will ultimately develop psoriatic arthritis? In today's episode, we explore a pivotal study that addresses this critical clinical question by developing and internally validating multivariable prediction models for new-onset psoriasis. The researchers utilized an inception cohort to create tools aimed at identifying patients suitable for prompt rheumatologist referral and predicting the progression to clinical psoriatic arthritis in those with subclinical symptoms. The most compelling finding is that key predictors, such as specific pain patterns, HLA-B27 positivity, and systemic inflammation markers like hs-CRP, are present right at the onset of skin disease, allowing these models to effectively stratify risk. However, when critically appraising this paper, it is crucial to note that the study relies on a modest sample size from a single geographic region, leading to some prediction instability in intermediate-risk groups, meaning external validation is essential before widespread implementation. For physicians, particularly general practitioners and dermatologists, this study is highly relevant; it provides a much-needed objective framework to streamline early referrals and targeted monitoring, potentially preventing irreversible joint damage through timely intervention.

Citation: Svedbom A, Mallbris L, Zabotti A, Playford MP, Nikamo P, Mehta NN, Ståhle M. Predicting psoriatic arthritis in new-onset psoriasis: development of multivariable prediction models from an inception cohort study. Lancet Rheumatology. 2026. DOI: 10.1016/S2665-9913(26)00115-3

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.